From: Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience
all patients
patients receiving systemic therapy only
patients receiving surgical intervention
n = 32
n = 23
n = 9
PFS median (range)
3.1 (0.6–16.2)
2.8 (0.6–16.2)
4.7 (2.1–11.9)
OS median (range)
4.6 (1.6–17.5)
3.9 (1.6–17.5)
7.4 (3.3–16.6)